Publications by authors named "R Hopewell"
Article Synopsis
- This study focuses on identifying individuals with advanced Alzheimer's disease (specifically Braak V or VI) using plasma biomarkers in those who are already confirmed to have amyloid-β (Aβ).
- Researchers evaluated 595 participants from two studies, employing tests like amyloid-PET and tau-PET while measuring various plasma tau levels.
- Findings suggest that elevated levels of plasma pTau-217 are strongly associated with Braak V positivity, indicating it could be a useful biomarker for patient stratification in treatment and clinical studies.
Article Synopsis
- The study aimed to compare the in vitro binding characteristics of three radiotracers ([F]flortaucipir, [F]MK6240, [F]PI2620) in postmortem brain samples from Alzheimer’s disease (AD) and control groups.
- Significant differences in tracer binding were found in the whole-brain hemisphere, prefrontal cortex, and hippocampus between AD and control tissues, with [F]MK6240 and [F]PI2620 showing better performance in differentiating AD cases.
- The results indicate that [F]MK6240 and [F]PI2620 have higher selectivity and binding to AD tissues compared to [F]flortaucipir,
Positron Emission Tomography (PET) ligands have advanced Alzheimer's disease (AD) diagnosis and treatment. Using autoradiography and cryo-EM, we identify AD brain tissue with elevated tau burden, purify filaments, and determine the structure of second-generation high avidity PET ligand MK-6240 at 2.31 Å resolution, which bound at a 1:1 ratio within the cleft of tau paired-helical filament (PHF), engaging with glutamine 351, lysine 353, and isoleucine 360.
View Article and Find Full Text PDFBackground: Radiolabeling is critical in complex chemical reactions involving positron emission tomography (PET) radiotracer production. The process is now automated within a synthesis module to enhance efficiency and reduce radiation exposure. The key to this automation is the use of radiation detectors to monitor radioactivity transfer and ensure the progression of reactions.
View Article and Find Full Text PDFPositron Emission Tomography (PET) ligands have advanced Alzheimer's disease (AD) diagnosis and treatment. Using autoradiography and cryo-EM, we identified AD brain tissue with elevated tau burden, purified filaments, and determined the structure of second-generation high avidity PET ligand MK-6240 at 2.31 Å resolution, which bound at a 1:1 ratio within the cleft of tau paired-helical filament (PHF), engaging with glutamine 351, lysine K353, and isoleucine 360.
View Article and Find Full Text PDF